GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » 5-Year Yield-on-Cost %

HUMA (Humacyte) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 11, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte 5-Year Yield-on-Cost %?

Humacyte's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Humacyte's 5-Year Yield-on-Cost % or its related term are showing as below:



HUMA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.785
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Humacyte's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Humacyte's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Humacyte's 5-Year Yield-on-Cost % falls into.


;
;

Humacyte 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Humacyte is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Humacyte  (NAS:HUMA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Humacyte 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Humacyte's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace director 210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411

Humacyte Headlines

From GuruFocus